Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status

Behavioural Brain Research

Volumn 216, Issue 1, 2011, Pages 255-261

  Rodriguez Rivera, Jennifer ^a   Denner, Larry ^a,b   Dineley, Kelly T ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Alzheimer's disease; Fear conditioning; Glucose tolerance test; Hippocampus dependent learning and memory; Insulin; Mouse model; PPAR

Indexed keywords

GLUCOSE; ROSIGLITAZONE;

AGE; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; MALE; MEMORY DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATE DEPENDENT LEARNING; TREATMENT DURATION;

ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANIMALS; AREA UNDER CURVE; ASSOCIATION LEARNING; BLOOD GLUCOSE; COGNITION; DISEASE MODELS, ANIMAL; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN; MEMORY; MICE; MICE, TRANSGENIC; THIAZOLIDINEDIONES;

EID: 78149407291     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.08.002     Document Type: Article

References (39)

1. Alzheimer's disease facts and figures. Alzheimers Dement 2009, 5(3):234-270. Alzheimer's Association.
2. Larson E.B., Kukull W.A., Katzman R.L. Cognitive impairment: dementia and Alzheimer's disease. Annu Rev Public Health 1992, 13:431-449.
3. Forstl H., Kurz A. Clinical features of Alzheimer's disease. Eur Arch Psychiatr Clin Neurosci 1999, 249(6):288-290.
4. Luchsinger J.A., Tang M.X., Shea S., Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004, 63(7):1187-1192.
5. Ott A., Stolk R.P., van Harskamp F., Pols H.A., Hofman A., Breteler M.M. Diabetes mellitus and the risk of dementia: the rotterdam study. Neurology 1999, 53(9):1937-1942.
6. Luchsinger J.A., Tang M.X., Stern Y., Shea S., Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001, 154(7):635-641.
7. Xu W.L., Qiu C.X., Wahlin A., Winblad B., Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 2004, 63(7):1181-1186.
8. Arvanitakis Z., Wilson R.S., Bienias J.L., Evans D.A., Bennett D.A. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004, 61(5):661-666.
9. Craft S., Asthana S., Schellenberg G., Cherrier M., Baker L.D., Newcomer J., et al. Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology 1999, 70(2):146-152.
10. Jiang Q., Heneka M., Landreth G.E. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs 2008, 22(1):1-14.
11. Watson G.S., Cholerton B.A., Reger M.A., Baker L.D., Plymate S.R., Asthana S., et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatr 2005, 13(11):950-958.
12. Risner M.E., Saunders A.M., Altman J.F., Ormandy G.C., Craft S., Foley I.M., et al. Efficacy of rosiglitazone in a genetically defined population with mild to moderate Alzheimer's disease. Pharmacogenomics J 2006, 6(4):246-254.
13. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., et al. Correlative memory deficits, abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274(5284):99-102.
14. Dineley K.T., Xia X., Bui D., Sweatt J.D., Zheng H. Accelerated plaque accumulation, associative learning deficits and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J Biol Chem 2002, 277(25):22768-22780.
15. Irizarry M.C., McNamara M., Fedorchak K., Hsiao K., Hyman B.T. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 1997, 56(9):965-973.
16. Irizarry M.C., Soriano F., McNamara M., Page K.J., Schenk D., Games D., et al. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 1997, 17(18):7053-7059.
17. Chapman P.F., White G.L., Jones M.W., Cooper-Blacketer D., Marshall V.J., Irizarry M., et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 1999, 2(3):271-276.
18. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 2001, 21(2):372-381.
19. Westerman M.A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L.H., et al. The relationship between abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 2002, 22(5):1858-1867.
20. Dineley K.T., Hogan D., Zhang W.R., Taglialatela G. Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. Neurobiol Learn Mem 2007, 88(2):217-224.
21. Taglialatela G., Hogan D., Zhang W.R., Dineley K.T. Intermediate- and long-term recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition. Behav Brain Res 2009, 200(1):95-99.
22. Pedersen W.A., Flynn E.R. Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Dis 2004, 17(3):500-506.
23. Pedersen W.A., McMillan P.J., Kulstad J.J., Leverenz J.B., Craft S., Haynatzki G.R. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 2006, 199(2):265-273.
24. Cao D., Lu H., Lewis T.L., Li L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J Biol Chem 2007, 282(50):36275-36282.
25. Ho L., Qin W., Pompl P.N., Xiang Z., Wang J., Zhao Z., et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 2004, 18(7):902-904.
26. Escribano L., Simon A.M., Perez-Mediavilla A., Salazar-Colocho P., Del Rio J., Frechilla D. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem Biophys Res Commun 2009, 379(2):406-410.
27. McShane R., Areosa Sastre A., Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006, 2. CD003154.
28. Craft S., Watson G.S. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004, 3(3):169-178.
29. Watson G.S., Bernhardt T., Reger M.A., Cholerton B.A., Baker L.D., Peskind E.R., et al. Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease. Neurobiol Aging 2006, 27(1):38-41.
30. Wickelgren I. Tracking insulin to the mind. Science 1998, 280(5363):517-519.
31. Craft S., Asthana S., Cook D.G., Baker L.D., Cherrier M., Purganan K., et al. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 2003, 28(6):809-822.
32. Park C.R., Seeley R.J., Craft S., Woods S.C. Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol Behav 2000, 68(4):509-514.
33. Craft S., Peskind E., Schwartz M.W., Schellenberg G.D., Raskind M., Porte D. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998, 50(1):164-168.
34. Wallum B.J., Taborsky G.J., Porte D., Figlewicz D.P., Jacobson L., Beard J.C., et al. Cerebrospinal fluid insulin levels increase during intravenous insulin infusions in man. J Clin Endocrinol Metab 1987, 64(1):190-194.
35. Baura G.D., Foster D.M., Kaiyala K., Porte D., Kahn S.E., Schwartz M.W. Insulin transport from plasma into the central nervous system is inhibited by dexamethasone in dogs. Diabetes 1996, 45(1):86-90.
36. Saha P.K., Kojima H., Martinez-Botas J., Sunehag A.L., Chan L. Metabolic adaptations in the absence of perilipin: increased beta-oxidation and decreased hepatic glucose production associated with peripheral insulin resistance but normal glucose tolerance in perilipin-null mice. J Biol Chem 2004, 279(34):35150-35158.
37. Kohjima M., Sun Y., Chan L. Increased food intake leads to obesity and insulin resistance in the tg2576 Alzheimer's disease mouse model. Endocrinology 2010, 151(4):1532-1540.
38. Nicolakakis N., Aboulkassim T., Ongali B., Lecrux C., Fernandes P., Rosa-Neto P., et al. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist. J Neurosci 2008, 28(37):9287-9296.
39. Watson G., Baker L.D., Rhoads K.W., Cholerton B.A., Reger M.A., Belongia D.A., Fishel M.A., Kahn S.E., Playmate S.R., Craft S. The PPAR-γ agonist pioglitazone facilitates verbal memory and improves insulin sensitivity in glucose intolerant older adults. 2007 Neuroscience Meeting Planner 2007, Society for Neuroscience, San Diego, CA, Program No. 525.4. Online.